

Date of preparation: 2022-02-24

Abbreviated name of the Issuer: MABION S.A.

Subject matter: Decision to abandon further implementation of the research project on the development of MabionEGFR

Legal basis: Article 17(1) of MAR – confidential information.

Content of the Report:

With reference to Current Report no. 48/2017 of 4 October 2017 concerning the agreement with the National Centre for Research and Development (NCBR) on co-financing of the research project related to development of MabionEGFR, titled "Development of a biotechnology medicine by developing an innovative monoclonal antibody of IgG1 subclass with reduced content of unfavourable glycoforms in comparison to the reference medicine - targeted against EGFR" as part of the Sectoral Programme: InnoNeuroPharm (competition 2/1.2/2017/POIR) Measure 1.2: "Sectoral R&D programmes", financed from SGOP 2014-2020 ("Project"), the Management Board of Mabion S.A. ("Company", "Issuer") hereby informs of the decision to abandon further implementation of the Project due to the fact that, in the opinion of the Management Board, further implementation of the Project is unjustified.

As a result of the decision and in accordance with the provisions of the co-financing agreement, the Company will soon apply to the NCBR for the final payment together with the final information on the Project implementation. Under the agreement, the value of co-financing was approximately PLN 28 million, of which, to date, the Company has submitted payment applications to the NCBR for co-financing at a level of approximately PLN 4 million. The final amount of received co-financing will be determined by the NCBR after the evaluation of documents submitted by the Company, including the documents indicated above.